The medical-industrial complex was scrutinized
Why it matters: Remember the controversy that surrounded the
FDA's decision in June to approve aducanumab for the treatment of Alzheimer's
disease? This analysis looks at the controversy from numerous angles and shines
a spotlight on what can happen when a hypothesis about a drug or target for
treatment becomes "too big to fail."
Full Story: Scientific
American (tiered subscription model) (8/2021)
No comments:
Post a Comment